Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moleculin Biotech (MBRX) Current Assets (2016 - 2025)

Moleculin Biotech (MBRX) has 10 years of Current Assets data on record, last reported at $7.9 million in Q3 2025.

  • For Q3 2025, Current Assets fell 32.06% year-over-year to $7.9 million; the TTM value through Sep 2025 reached $7.9 million, down 32.06%, while the annual FY2024 figure was $5.2 million, 80.23% down from the prior year.
  • Current Assets reached $7.9 million in Q3 2025 per MBRX's latest filing, down from $9.1 million in the prior quarter.
  • Across five years, Current Assets topped out at $88.0 million in Q1 2021 and bottomed at $5.2 million in Q4 2024.
  • Average Current Assets over 5 years is $39.5 million, with a median of $35.4 million recorded in 2023.
  • Peak YoY movement for Current Assets: soared 405.38% in 2021, then plummeted 80.23% in 2024.
  • A 5-year view of Current Assets shows it stood at $72.5 million in 2021, then plummeted by 37.11% to $45.6 million in 2022, then crashed by 42.38% to $26.3 million in 2023, then tumbled by 80.23% to $5.2 million in 2024, then soared by 51.81% to $7.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Current Assets were $7.9 million in Q3 2025, $9.1 million in Q2 2025, and $9.3 million in Q1 2025.